MGMT and glioblastoma: The two ongoing phase 3 trials CheckMate-498 and CheckMate-548 evaluating the use of nivolumab in patients with newly-diagnosed GBM, either methylguanine methyltransferase (MGMT)-unmethylated or MGMT-methylated, also failed to meet their primary endpoints, according to an update by Bristol-Myers Squibb.